Abstract
ERCC1 mRNA expression is associated with the clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy
Author(s): H. Zhang1, J. Li2, Y. Zhang2, M. Sun3, P. Zhao1, G. Zhang2, C. Jin2, L. Sun1, M. He1, B. Wang2 and X. Zhang2We conducted a prospective study to analyze the expression of the excision repair cross-complementing group 1 (ERCC1) and ribonucleotide reductase subunit M1 (RRM1) genes in 297 Chinese patients with advanced non-small cell lung cancer (NSCLC). The goal of this study was to evaluate these genes as potential biomarkers for prediction of tumor response and clinical outcome.
